In this autoimmune disease, the body’s immune system attacks healthy skin. There are 3 main types: (1) Acute cutaneous lupus (“acute skin lupus”); (2) Subacute cutaneous lupus (“subacute lupus”); and (3) Chronic cutaneous lupus (“discoid lupus”). All patients with skin lupus need to be monitored for disease inside of the body, which can affect the joints, kidneys, lungs, and other organs. Acute skin lupus almost always involves more than just the skin, whereas both subacute and discoid lupus often occur only in the skin. This is important because while all patients with skin lupus need to be monitored, many patients with either subacute lupus or discoid lupus go through life without significant disease inside their bodies.
Market Analysis and Insights: Global and United States Cutaneous Lupus Erythematosus (CLE) Treatment Market
This report focuses on global and United States Cutaneous Lupus Erythematosus (CLE) Treatment market, also covers the segmentation data of other regions in regional level and county level.
Due to the COVID-19 pandemic, the global Cutaneous Lupus Erythematosus (CLE) Treatment market size is estimated to be worth US$ 310.5 million in 2022 and is forecast to a readjusted size of US$ 437.9 million by 2028 with a CAGR of 5.9% during the review period. Fully considering the economic change by this health crisis, by Type, Topical accounting for % of the Cutaneous Lupus Erythematosus (CLE) Treatment global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While by Application, Hospitals was the leading segment, accounting for over percent market share in 2021, and altered to an % CAGR throughout this forecast period.
The classification of Cutaneous Lupus Erythematosus (CLE) Treatment includes Topical Treatments and Systemic Treatments. And the proportion of Systemic Treatments in 2019 is about 73%, and the proportion of Topical Treatments in 2019 is about 26%.
Cutaneous Lupus Erythematosus (CLE) Treatment is widely used for Hospitals, Drugstores and Others. The most proportion of Cutaneous Lupus Erythematosus (CLE) Treatment is Drugstores, and the proportion in 2019 is 68.59%.
North America is the largest consumption place, with a consumption market share nearly 44.6 % in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 27.89%.
Global Cutaneous Lupus Erythematosus (CLE) Treatment Scope and Market Size
Cutaneous Lupus Erythematosus (CLE) Treatment market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Cutaneous Lupus Erythematosus (CLE) Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the Cutaneous Lupus Erythematosus (CLE) Treatment market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
Topical
Systemic treatments
Segment by Application
Hospitals
Drugstores
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
GSK
Pfizer
AstraZeneca
ImmuPharma
Biogen
Viela Bio
Roche
Bristol-Myers Squibb